All Stories

  1. Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

    Article • BioMed Research International, January 2019, Hindawi Publishing Corporation

    Dr Leif G Carlsson

  2. Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans

    Article • EP Europace, July 2014, European Society of Cardiology

    Dr Leif G Carlsson, Dr Hakan Walfridsson

  3. Assessment of Ventricular Repolarization Variability with the DeltaT50 Method Improves Identification of Patients with Congenital Long QT Syndromes

    Article • Annals of Noninvasive Electrocardiology, November 2012, Wiley

    Dr Leif G Carlsson

  4. Novel molecular targets for atrial fibrillation therapy

    Article • Nature Reviews Drug Discovery, March 2012, Springer Science + Business Media

    Dr Leif G Carlsson

  5. DeltaT50—a new method to assess temporal ventricular repolarization variability

    Article • Journal of Electrocardiology, July 2011, Elsevier

    Dr Leif G Carlsson

  6. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit

    Article • Journal of Pharmacological and Toxicological Methods, January 2011, Elsevier

    Dr Leif G Carlsson

  7. New pharmacological targets and treatments for atrial fibrillation

    Article • Trends in Pharmacological Sciences, August 2010, Elsevier

    Dr Leif G Carlsson

  8. AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog

    Article • Journal of Cardiovascular Pharmacology, July 2010, Wolters Kluwer Health

    Dr Leif G Carlsson

  9. AZD1305 has Atrial-Predominant Electrophysiologic Actions and is Effective in Suppressing Atrial Fibrillation in the Dog

    Article • Heart Rhythm, November 2009, Elsevier

    Dr Leif G Carlsson

  10. Potent Antiarrhythmic Effects of Chronic Amiodarone in Canine Pulmonary Vein Sleeve Preparations

    Article • Journal of Cardiovascular Electrophysiology, July 2009, Wiley

    Dr Leif G Carlsson

  11. Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo

    Article • Journal of Cardiovascular Pharmacology, July 2009, Wolters Kluwer Health

    Dr Leif G Carlsson

  12. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation

    Article • Heart Rhythm, December 2008, Elsevier

    Dr Leif G Carlsson

  13. Model systems for the discovery and development of antiarrhythmic drugs

    Article • Progress in Biophysics and Molecular Biology, October 2008, Elsevier

    Dr Leif G Carlsson

  14. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes

    Article • Pharmacology & Therapeutics, August 2008, Elsevier

    Dr Leif G Carlsson

  15. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre

    Article • European Journal of Pharmacology, March 2007, Elsevier

    Dr Leif G Carlsson

  16. Innovative approaches to anti-arrhythmic drug therapy

    Article • Nature Reviews Drug Discovery, December 2006, Springer Science + Business Media

    Dr Leif G Carlsson

  17. Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog

    Article • Journal of Cardiovascular Pharmacology, January 2006, Wolters Kluwer Health

    Dr Leif G Carlsson

  18. Assessment of the Proarrhythmic Potential of the Novel Antiarrhythmic Agent AZD7009 and Dofetilide in Experimental Models of Torsades De Pointes

    Article • Journal of Cardiovascular Electrophysiology, August 2005, Wiley

    Dr Leif G Carlsson

  19. Blocking Characteristics of hKv1.5 and hKv4.3/hKChIP2.2 After Administration of the Novel Antiarrhythmic Compound AZD7009

    Article • Journal of Cardiovascular Pharmacology, July 2005, Wolters Kluwer Health

    Dr Leif G Carlsson

  20. Blocking Characteristics of hERG, hNav1.5, and hKvLQT1/hminK after Administration of the Novel Anti-Arrhythmic Compound AZD7009

    Article • Journal of Cardiovascular Electrophysiology, March 2005, Wiley

    Dr Leif G Carlsson

  21. AZD7009:

    Article • Journal of Cardiovascular Electrophysiology, December 2004, Wiley

    Dr Leif G Carlsson

  22. Block of HERG‐Carried K + Currents by the New Repolarization Delaying Agent H 345/52

    Article • Journal of Cardiovascular Electrophysiology, June 2003, Wiley

    Dr Leif G Carlsson

  23. Comparison of the Proarrhythmic Effect of GLG-V-13, a Novel Class III Antiarrhythmic Compound, in Two Rabbit Models of Torsades de Pointes Ventricular Tachycardia

    Article • Annals of Noninvasive Electrocardiology, January 1997, Wiley

    Dr Leif G Carlsson

  24. Lidocaine and Nisoldipine Attenuate Almokalant-Induced Dispersion of Repolarization and Early Afterdepolarizations In Vitro

    Article • Journal of Cardiovascular Electrophysiology, November 1996, Wiley

    Dr Leif G Carlsson

  25. Electrophysiological and Inotropic Characterization of a Novel Class III Antiarrhythmic Agent, GLG-V-13, in the Mammalian Heart

    Article • Journal of Cardiovascular Pharmacology, August 1996, Wolters Kluwer Health

    Dr Leif G Carlsson

  26. Prevention of Class III-Induced Proarrhythmias by Flecainide in an Animal Model of the Acquired Long QT Syndrome

    Article • Pharmacology & Toxicology, October 1995, Wiley

    Dr Leif G Carlsson

  27. Electrophysiologic and Hemodynamic Effects of H 234/09 (Almokalant), Quinidine, and (+)-Sotalol in the Anesthetized Dog

    Article • Journal of Cardiovascular Pharmacology, December 1992, Wolters Kluwer Health

    Dr Leif G Carlsson

  28. Electrophysiologic and Hemodynamic Effects of H 234/09 (Almokalant), Quinidine, and (+)-Sotalol in the Anesthetized Dog

    Article • Journal of Cardiovascular Pharmacology, September 1992, Wolters Kluwer Health

    Dr Leif G Carlsson

  29. Prolonged Action Potential Duration and Positive Inotropy Induced by the Novel Class III Antiarrhythmic Agent H 234/09 (Almokalant) in Isolated Human Ventricular Muscle

    Article • Journal of Cardiovascular Pharmacology, December 1991, Wolters Kluwer Health

    Dr Leif G Carlsson

  30. Cardioprotective Effects of Recombinant Human Extracellular-Superoxide Dismutase Type C in Rat Isolated Heart Subjected to Ischemia and Reperfusion

    Article • Journal of Cardiovascular Pharmacology, April 1991, Wolters Kluwer Health

    Dr Leif G Carlsson

  31. QTU-Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit

    Article • Journal of Cardiovascular Pharmacology, August 1990, Wolters Kluwer Health

    Dr Leif G Carlsson

  32. Ramilprilat attenuates the local release of noradrenaline in the ischemic myocardium

    Article • European Journal of Pharmacology, July 1989, Elsevier

    Dr Leif G Carlsson

  33. Release of Noradrenaline in Myocardial Ischemia—Importance of Local Inactivation by Neuronal and Extraneuronal Mechanisms

    Article • Journal of Cardiovascular Pharmacology, May 1986, Wolters Kluwer Health

    Dr Leif G Carlsson

  34. Local Release of Myocardial Norepinephrine During Acute Ischemia

    Article • Journal of Cardiovascular Pharmacology, July 1985, Wolters Kluwer Health

    Dr Leif G Carlsson

  35. Antiarrhythmic Effect of Reducing Myocardial Noradrenaline Stores with α-Methyl-Meta-Tyrosine

    Article • Journal of Cardiovascular Pharmacology, January 1985, Wolters Kluwer Health

    Dr Leif G Carlsson